A 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
Can atezolizumab succeed where BCG fails in bladder cancer?
Advancements in use of combination drugs in clinical trials: nivolumab, pembrolizumab, and more
Mechanisms of resistance to checkpoint inhibitors in melanoma
The importance of cancer nursing educators